Published in final edited form as:

Neuromolecular Med. 2008 ; 10(3): 195–207. doi:10.1007/s12017-008-8035-0.

Maximizing the Potential of Plasma Amyloid-beta as a Diagnostic Biomarker for Alzheimer's Disease

Esther S. Oh, M.D.^{a,b,*}, Juan C. Troncoso, M.D.^{b,c}, and Stina M. Fangmark Tucker, Ph.D.

^aDepartment of Medicine, The Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Ave., Baltimore, MD

^bDepartment of Pathology, The Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Ave., Baltimore, MD

^cDepartment of Neurology, The Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Ave., Baltimore, MD

Abstract

Amyloid plaques are composed primarily of amyloid-beta (A β) peptides derived from proteolytic cleavage of amyloid precursor protein (APP), and are considered to play a pivotal role in Alzheimer's disease (AD) pathogenesis. Presently, AD is diagnosed after the onset of clinical manifestations. With the arrival of novel therapeutic agents for treatment of AD, there is an urgent need for biomarkers to detect early stages of AD. Measurement of plasma A β has been suggested as an inexpensive and non-invasive tool to diagnose AD and to monitor A β modifying therapies. However, the majority of cross-sectional studies on plasma A β levels in humans have not shown differences between individuals with AD compared to controls. Similarly, cross-sectional studies of mouse plasma A β have yielded inconsistent trends in different mouse models. However, longitudinal studies appear to be more promising in humans. Recently, efforts to modify plasma A β levels using modulators have shown some promise. In this review, we will summarize the present data on plasma A β in humans and mouse models of AD. We will discuss the potential of modulators of A β levels in plasma including antibodies and insulin, and the challenges associated with measuring plasma A β . Modulators of plasma A β may provide an important tool to optimize plasma A β levels, and may improve the diagnostic potential of this approach.

Keywords

Alzheimer's disease; Plasma; Biomarker; Human; Transgenic mouse model of AD

Introduction

The pathological hallmarks of Alzheimer's disease (AD) are amyloid plaques, neurofibrillary tangles, synaptic degeneration and neuronal loss (Price and Sisodia, 1998). Amyloid plaques are composed of amyloid-beta (A β) 42 and 40 peptides derived from the proteolytic cleavage of amyloid precursor protein (APP) by β -site APP cleavage enzyme 1 (BACE1) (Sinha et al., 1999; Vassar et al., 1999) and the γ -secretase (De Strooper, 2003). The Endosome and the endocytic pathway have been proposed as possible sites for the β and γ cleavage sites of APP

*Corresponding Author: Esther S. Oh, M.D., 558 Ross Research Building, 720 Rutland Ave., Baltimore, MD 21205, phone: (410-955-5632), fax: (410-955-9777), e-mail: Eoh9@jhmi.edu.

[§]Present address: Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Dag Hammarskjölds Väg 20, SE-751 85 Uppsala, Sweden.

(Small and Gandy, 2006), and the resulting A β peptides are secreted by both neuronal and non-neuronal cells (Selkoe, 1997; Selkoe, 2002). Recently, soluble forms of A β have been implicated in neurotoxicity (Lambert et al., 1998; Walsh et al., 2002; Lesne et al., 2006), and may correlate better with cognition than amyloid plaque burden (Lue et al., 1999; McLean et al., 1999).

The clinical manifestations of AD, i.e cognitive decline and neuro-behavioral changes, are preceded by a long preclinical stage characterized by the silent development of neuropathological lesions (Crystal et al., 1988; Katzman et al., 1988; Troncoso et al., 1996; Price and Morris, 1999; Schmitt et al., 2000; Morris and Price, 2001). These preclinical and early stages of AD represent the ideal time to treat the disease (Neugroschl and Davis, 2002) with newly emerging approaches such as gamma-secretase inhibitors (Siemers et al., 2006; Siemers et al., 2007) or immunotherapy (Hock et al., 2003).

As A β is considered to play an early and pivotal role in AD pathogenesis (Hardy and Selkoe, 2002), it may be a useful tool in diagnosing AD in the preclinical/early stages, as well as for monitoring potential A β modifying therapies (Galasko, 2005). While human CSF A β levels have mostly shown reduction with disease progression (Jensen et al., 1999), much of the data on plasma A β levels have been equivocal (Irizarry, 2004). However, since plasma A β would be less invasive and more accessible than CSF A β as a biomarker, many strategies are under investigation to optimize plasma A β as a predictor of AD as well as to monitor the efficacy of A β modifying agents.

In this paper, we will review studies involving plasma A β levels in humans as well as in transgenic (tg) mouse models of AD. Further, we will discuss the challenges that arise in measuring plasma A β levels as well as ways to optimize the detection of A β in plasma.

Plasma A β Levels

Human Data

While the data on human cerebrospinal fluid (CSF) mostly show decreased A β levels correlating with diagnosis and disease progression of AD (Jensen et al., 1999; Sunderland et al., 2003), much of the data on human plasma A β remain unclear. Studies have shown that subjects who exhibit overproduction of A β such as individuals with familial forms of AD and Down's syndrome have higher plasma A β levels compared to controls (Scheuner et al., 1996; Tokuda et al., 1997; Iwatsubo, 1998). However, only 5–10% of the AD cases are familial (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995) and the remaining cases are mostly sporadic (sAD) and late-onset AD (LOAD). While A β production is thought to be increased in FAD (Selkoe, 2001), sAD is thought to be caused by the imbalance between A β production and clearance (Selkoe, 2001; Hardy and Selkoe, 2002). Many of the cross-sectional studies examining sAD subjects have not shown significant difference in the plasma A β levels compared to cognitively normal controls or controls with other neurological diseases (Table 1).

There may be several reasons why the data on plasma A β levels in sAD subjects are less consistent compared to CSF A β levels. Direct communication between the brain interstitial fluid (ISF) and CSF (Silverberg et al., 2003) may allow the A β level in the brain ISF to be closely reflected in the CSF. It is thought that decreasing CSF A β levels with progression of AD is a reflection of increasing A β deposition into insoluble plaques in the brain, as well as decreasing numbers of neurons that are able to produce A β in the brain (Jensen et al., 1999). In plasma, interpretation of the A β level is more complex. In addition to variability found with age and disease severity (Giedraitis et al., 2007), there are other factors that come into play. One of the factors is the origin of A β in the plasma. There is evidence to suggest that most of

the A β production occurs in the brain (Laird et al., 2005), however the possibility of A β derived from other sources must be considered. Proteolytic processing of APP by BACE 1 leads to the formation of A β . BACE 1 activity can be found at very high levels in the AD brain (Holsinger et al., 2002; Yang et al., 2003), but is also present at lower levels in peripheral organs such as skeletal muscle, liver, kidney and lung (Sinha et al., 1999; Vassar et al., 1999). A β peptides have also been detected in skin, subcutaneous tissue and intestine (Joachim et al., 1989) as well as in muscle (Kuo et al., 2000b). Although the formation of A β species may be higher in the brain compared to other organs, it is possible that production of A β in large peripheral organs such as skeletal muscles which comprises approximately 25% of the body weight in humans may result in a significant contribution to the plasma A β pool (Kuo et al., 2000b). Platelets are another source of A β , albeit mostly A β 40 (Bush et al., 1990; Chen et al., 1995; Evin et al., 2003). Detection of lower A β levels (1:2) in the ventricular CSF samples compared to the spinal CSF samples also suggest contribution of A β from periphery (de Leon et al., 2004).

Another factor that may confound the detection of A β is the transporter dependent movement of A β into and from the brain. Animal data suggest that approximately 10 % of A β from the brain interstitial fluid (ISF) moves into blood stream via ISF bulk flow (Shibata et al., 2000). However, most of the movement of A β is thought to be dependent on transporters such as low-density lipoprotein receptor-related protein-1 (LRP-1) (Deane et al., 2004; Shibata et al., 2000) and receptor for advanced glycation end products (RAGE) (Deane et al., 2003) due to the presence of tight endothelial cell junctions at the blood brain barrier (BBB) (Begley and Brightman, 2003). Taken together, these reasons may explain the difficulty in establishing a direct correlation between plasma A β and CSF A β levels (Vanderstichele et al., 2000; Mehta et al., 2001; Giedraitis et al., 2007; Matsumoto et al., 2007). Further, these factors may explain why plasma A β levels do not correlate well with brain A β levels at autopsy (Freeman et al., 2007) or in vivo imaging by PIB compound (Fagan et al., 2006) in AD cases.

One interesting finding observed in several of these studies is the effect of aging on plasma A β levels in humans (Matsubara et al., 1999; Mayeux et al., 1999; Fukumoto et al., 2003; Mayeux et al., 2003; Ertekin-Taner et al., 2008; Sundelof et al., 2008). Specifically, increase in age alone correlated with increase in plasma A β levels in some studies. This was demonstrated in cognitively normal adults (Matsubara et al., 1999) as well as in sAD/MCI and other neurological controls (Fukumoto et al., 2003). This increase may be due to aging related changes. Tamaki et al. demonstrated decreased levels of hepatic LRP-1 with concomitant decrease in hepatic A β 40 uptake in aged versus young rats (Tamaki et al., 2006). If the same holds true for humans, decreased peripheral uptake and clearance of A β in the liver may be contributing to the increase in plasma A β levels in older adults.

The effects of aging also complicate the interpretation of plasma A β levels. It is possible that gradual decrease in plasma A β levels in the AD group may eventually fall to the same range as the normal controls whose plasma A β levels increase in age dependent manner (Golde et al., 2000). This may explain why much of the plasma A β data in cross-sectional studies do not show significant differences between sAD and controls. The longitudinal studies seem more promising, with some studies showing initially elevated A β 42 levels in those that eventually develop AD in the future (Mayeux et al., 1999; Mayeux et al., 2003). Most show that subjects who manifest sAD within the time frame of the study start with higher plasma A β 42 levels, and the A β 42/A β 40 ratios also appear to be significantly different from those who remain asymptomatic, albeit different patterns that have been observed in different studies (Table 1) (Mayeux et al., 1999; Graff-Radford et al., 2007). It may also be important to understand the genetics of sAD in order to correctly interpret plasma A β levels, as plasma A β 42 was shown to be elevated in the extended family members of some of the subjects with sAD or LOAD (Ertekin-Taner et al., 2001; Ertekin-Taner et al., 2008).

Recently, different studies have investigated the time dependent variability of A β levels in CSF. One study has shown that CSF A β levels are thought to have significant variability (1.5 to fourfold) over 12 to 36 hours, and that they may be dependent on the time of day or activity (Bateman et al., 2007), while other studies have shown that they are stable up to an average of 10 to 18 months of follow up (Kanai et al., 1998; Andreasen et al., 1999). Plasma A β surprisingly has less variability, with remarkable reproducibility over a 3 day period in 19 subjects. There was a small but significant difference in the levels measured in the morning versus afternoon. There was also a good reproducibility in 32 subjects from a different cohort over a 12 week period (Ertekin-Taner et al., 2008).

Taken together, the interpretation of the cross-sectional studies may be complicated by the complex nature of plasma A β , whereas longitudinal studies of plasma A β may be a better indicator of disease progression. Further investigations are necessary to understand A β production and clearance, and may lead to a better understanding of the diagnostic potential of plasma A β .

Mouse Data

In addition to endogenous mouse APP expression, transgenic mice overexpress human APP under the regulation of a specific promoter element. Endogenous mouse APP is found primarily in the brain and lung with lower levels of expression in the spleen, stomach, large intestine and skin (Kawarabayashi et al., 2001). The promoter that drives the transgene dictates the expression of human APP in mouse models of AD, hence, this expression is highly model specific. For example, in Tg2576 mice human APP is expressed at high levels in brain, spleen and lung, with lower levels of transgene expression in skin, bone, muscle, heart, pancreas, stomach, and large intestine (Kawarabayashi et al., 2001). BACE 1 expression, which is necessary for the formation of A β 42, is limited to the brain of wild type mice by Western blot analysis (Laird et al., 2005). By sensitive ELISA measurements, A β has been detected at low levels in peripheral organs (10–24 pmol/g), whereas the levels in the brain were 20 to 40-fold higher in Tg2576 mice (Kawarabayashi et al., 2001). Therefore, the expression patterns of human APP and mouse BACE 1 are likely to affect the availability of A β in plasma, and should be considered when interpreting the plasma A β data from mouse models of AD.

Similar to the data in humans, plasma A β levels in AD mouse models are conflicting. Using the Tg2576 mouse model, Kawarabayashi et al. have shown that the plasma levels of A β are inversely related to A β plaque burden (Kawarabayashi et al., 2001). As mentioned above, A β formation in this model is high in the brain, but also present in peripheral organs (Kawarabayashi et al., 2001). As total brain levels of A β increased, indicating increasing plaque formation, CSF and plasma levels of A β concurrently decreased. This was not the case in wild type mice, and therefore could not be attributed to normal aging (Kawarabayashi et al., 2001).

A β levels in plasma and CSF in the PDAPP mouse model of AD do not correspond with the findings in Tg2576 mice. In these mice, human APP expression is found only in the brain by Western blotting (DeMattos et al., 2001). DeMattos et al. have reported a statistically significant positive correlation between CSF and plasma A β levels in young mice prior to the onset of amyloid deposition. However, a robust correlation between CSF and plasma A β was absent in older mice that were just beginning to accumulate amyloid plaques. If the older mouse cohort was divided into subsets by presence of amyloid plaques, the ratio of CSF to plasma A β was found to be twice as high in mice with amyloid plaques compared to mice without amyloid plaques. Unlike the observations by Kawarabayashi et al., this increase was attributed to higher CSF A β levels in the mice with amyloid plaques. Furthermore, the plasma A β levels did not correlate with the amyloid burden in the brain (DeMattos et al., 2002b). Hence, neither

the levels of plasma A β alone or the ratio of A β :CSF provided a clear cut prediction of amyloid formation in these mice.

Hence, the cross-sectional studies using mouse models of AD indicate that different models yield varying results, and corroborate the human data outlined in the previous section suggesting that such studies may not yield a reliable biomarker of early AD.

Challenges in Measuring Plasma A β

A factor that may contribute to the inconsistent data on plasma A β levels in both humans and transgenic mouse models of AD could be the difficulty in measuring A β by traditional ELISA assays. APP and other soluble APP fragments in biological samples may compete with A β peptides for capture and detection antibody in an ELISA assay (Golde et al., 2000). It has been shown that 6E10, a common antibody used in A β - specific ELISA assays, binds full-length APP, which could potentially interfere with the ability of 6E10 to sensitively detect A β species in plasma (Englund et al., 2007). Englund et al. have also demonstrated that an elevated level of A β protofibrils formed during the A β aggregation process leads to a reduced signal by traditional sandwich ELISA (Englund et al., 2007). Since oligomeric A β species are poorly detected by A β ELISA assays, only a subset of A β species present in the biological samples are accurately measured, leading to a potential underestimation of total A β levels (Stenh et al., 2005). Furthermore, presence of N-terminally truncated A β species in AD brains may create some problems for ELISA assays with N-terminal capture antibodies (Naslund et al., 1994; Ida et al., 1996).

A β binding proteins in the plasma also pose problems in measuring A β levels. Proteins such as albumin (Biere et al., 1996), α 2 macroglobulin (Kuo et al., 1999), various lipoproteins (Koudinov et al., 1994; Biere et al., 1996), and others (Kuo et al., 1999) are known to bind A β . Some studies have shown that large quantities of A β may remain “sequestered” by binding proteins, and interfere with ELISA quantification (Kuo et al., 2000a; Slemmon et al., 2007). This “masking” effect by the plasma binding proteins (Kuo et al., 1999) may also strengthen the case for longitudinal studies rather than cross-sectional studies. There is probably less variability in binding protein compositions within a subject than between subjects, as long as there has not been a major change in health that may affect binding proteins levels such as albumin.

Different steps in blood sample processing can also lead to underestimation of A β levels in plasma. Processing of the whole blood to plasma would spin down the platelets which are known to contribute to the blood A β pool (Bush et al., 1990; Chen et al., 1995; Evin et al., 2003). However one study has demonstrated that over 90% of the A β appears to remain within the plasma component when compared to the A β levels in the whole blood prior to processing (Slemmon et al., 2007). Other steps in the sample processing that influence plasma A β detection has been reviewed previously (Vanderstichele et al., 2000).

Antibody-Modulated Plasma A β Levels

Although the utility of plasma A β as a biomarker for AD is difficult to interpret, and the data collected from CSF samples appear to be more consistent. The inherent challenges in measuring plasma A β may further limit the potential of this strategy. However, it has been proposed that the equilibrium of A β can be disturbed by the administration of an A β -binding agent, such as an A β -specific antibody, in the blood. By binding A β in the blood, the antibody can potentially sequester plasma A β , shifting the equilibrium of soluble A β species, and causing a net efflux of A β from the brain to the plasma (Figure 1) (DeMattos et al., 2001; DeMattos et al., 2002a). This hypothesis is designated the “peripheral sink mechanism” (DeMattos et al., 2001). Such an approach could maximize the levels of A β available for detection in the plasma. In the

following paragraphs we will outline the data in support for using A β -specific antibodies to detect plasma A β .

Human

Following antibody mediated amelioration of A β deposition and behavioral deficits after A β vaccinations in tg mouse models of AD (Janus et al., 2000; Morgan et al., 2000), Dodel et.al examined whether naturally occurring human antibodies which recognizes A β can be used for treatment of AD. The first study involving 7 subjects with neurological disorders receiving intravenous immunoglobulin (IVIG) demonstrated that there was a significant reduction in the CSF A β levels accompanied by a significant increase in serum A β (Dodel et al., 2002). In another study involving 5 AD patients, infusion of IVIG again resulted in decrease in CSF A β with increase in serum A β (Dodel et al., 2004). This was similar to the observations in the tg mouse models of AD (see below), but more studies will need to be conducted to determine whether the A β levels after IVIG can be used as a biomarker. In active immunization trials, generation of antibodies against A β was not associated with changes in CSF or plasma A β levels (Hock et al., 2003).

Mouse

In 2001, DeMattos et al. demonstrated that administration of an antibody against the midregion of A β (m266) was able to induce a rapid increase of A β total:IgG complex from 150 pg/mL basal level to at least 15,000 pg/mL 6 hours after i.v. antibody administration in young PDAPP mice prior to plaque onset (DeMattos et al., 2001). This group has previously shown that the unmodified plasma A β 40 levels in PDAPP mice do not correlate with brain amyloid plaque burden (DeMattos et al., 2002b), in concordance with the human studies outlined above. However, administration of the m266 antibody in this mouse model induced an efflux of A β 40 from the central nervous system (CNS) into the plasma that correlated with the brain amyloid plaque load (DeMattos et al., 2002a). The m266 antibody has also been utilized to demonstrate a dose dependent increase in plasma A β 40 levels in PDAPP transgenic mice following i.p. injections, which was accompanied by cognitive improvement, suggesting that antibody injection may also have therapeutic benefits (Dodart et al., 2002).

Levites et al. have further characterized the effect of A β antibody injection in young Tg2576 mice prior to the onset of amyloid plaque deposition. This group demonstrates a 25-fold increase in plasma levels of A β 42 within 1 day following intraperitoneal (i.p.) administration of 500 μ g Ab9 (a mouse monoclonal antibody with epitope within A β 1-16). Furthermore, an Ab9:A β 40 complex with a half-life of approximately 7 days is detected in the plasma. Preclearing the plasma with a protein A/G, which removes mouse IgG, abolished greater than 90% of the plasma A β ELISA signal. This data suggests that the majority of A β that is detected in plasma is bound to the injected antibody, and that the A β :antibody complex is not a classic immune complex subject to rapid clearance (Levites et al., 2006). This supports the idea that the administration of A β antibody in mouse models of AD may be a feasible approach to maximize the measurable levels of A β in the plasma.

In support of using a peripheral sink mechanism to enhance the detection of A β in blood, a number of studies have demonstrated enhanced levels of A β total, A β 40 and/or A β 42 after A β antibody administration (Table 2) (Lemere et al., 2003; Asami-Odaka et al., 2005a; Hartman et al., 2005; DaSilva et al., 2006; Gray et al., 2007; Takata et al., 2007). However, the increases in A β after A β antibody administration vary from 2-fold to approximately 1000-fold (Table 2), and in some cases there is no significant difference between antibody-induced A β levels and controls (Seabrook et al., 2006; Zamora et al., 2006). There is also considerable divergence in the plasma A β levels reported in two separate studies that employed the same antibody (m266) and the same mouse model (Table 2) (DeMattos et al., 2001; Dodart et al., 2002).

Patients at risk for AD may exhibit very mild elevations in soluble A β levels as compared to healthy controls, therefore it is possible that very large inductions in plasma A β are necessary to identify the at-risk population. This potential caveat needs to be further examined in order to ascertain the feasibility of antibody-induced A β levels as a diagnostic biomarker.

Furthermore, the increases in plasma A β levels are compared to different types of controls in the above mentioned studies, including pre-injection A β levels (DeMattos et al., 2001; Gray et al., 2007; Takata et al., 2007), A β levels in transgenic mice given vehicle (Dodart et al., 2002; Asami-Odaka et al., 2005a; DaSilva et al., 2006; Seabrook et al., 2006; Zamora et al., 2006), and A β immunized wild type mice (Lemere et al., 2003). All humans produce A β , but it is possible that people at risk for AD have a higher production of A β compared to normal controls. Similarly, non-transgenic mice produce endogenous A β at lower levels than transgenic AD mouse models. Therefore, non-transgenic mice, or mice producing human A β at a lower level, could serve as an appropriate control for studies testing the efficacy of agents that induce A β efflux from the brain to the blood, yet these types of controls are not always included. Instead, the increases in A β are commonly compared to “baseline” A β readings, which does not provide much information regarding if the A β elevations in patients at risk for AD would be distinguishable from those of a healthy individual. In addition, the range of controls used in these animal studies may account for some of the variability in plasma A β increases. The variations in fold-A β elevations may also be attributable to the A β antibodies, tg mouse models, injection routes, and detection systems used.

Moreover, plasma A β levels may change with age due to changes in clearance of the A β peptide (Tamaki et al., 2006). Hence, it will be important to determine the ability of A β antibodies to induce elevations in young transgenic mice that have not yet developed amyloid plaques, as it is crucial that AD can be detected prior to the onset of symptoms. This has been tested in one mouse model where A β levels were elevated by approximately 500% in pre-plaque mice and 250% in mice that had developed amyloid plaques (Takata et al., 2007). However, the dose of antibody administered in this study differed for the two age groups, making it difficult to directly compare the effectiveness of A β antibody to induce A β efflux from the brain at different ages (Table 2) (Takata et al., 2007).

In order to optimize antibody-induced increases in A β levels for a diagnostic test, the most suitable antibody (isotype, affinity, and epitope), injection route, kinetics and detection system must be determined. As will be discussed in the following paragraph, the detection of antibody-induced A β levels has its own set of inherent challenges.

Challenges in measuring antibody-induced plasma A β

Measurements of antibody-induced plasma A β levels may be confounded by the presence of a third antibody in the traditional sandwich ELISA design. In addition to the capture antibody (coating the ELISA plate) and the detection antibody (which detects the antigen bound to the capture antibody), the plasma A β that is measured in this assay may be complexed with the injected antibody used to sequester A β in the periphery. A β 42 is a small peptide and many of the A β antibody epitopes overlap, potentially leading to steric hindrance in detection assays such as ELISAs. Gray et al. have shown that ELISA measurements of A β in plasma using 1A10 as the capture antibody are abrogated if the plasma sample is spiked with antibody 1A10. However, ELISA readings can be restored to near 100% if the plasma is treated with 2% SDS before dilution and addition to the ELISA plate (Gray et al., 2007). Further, as mentioned previously, oligomeric species of A β are poorly detected by ELISA assays (Englund et al., 2007), a complication that is likely to persist when antibody-induced A β levels are measured.

Other modifiers of plasma A β / A β binding agents

Human

Similar to AD, insulin resistance syndrome is also prevalent in the US, and is associated with aging (Harris et al., 1998). Insulin receptors are present throughout peripheral tissues as well as in the brain (Schulinkamp et al., 2000). There are in vitro data suggesting that insulin increases extracellular A β by reducing insulin degrading enzyme (IDE)-mediated A β degradation (Qiu et al., 1998). In addition to competing with A β for IDE, insulin facilitates trans-Golgi network (TGN) transport of A β , and increases A β secretion (Gasparini et al., 2001). Hence, systemic insulin levels may affect the levels of plasma A β .

In humans, age-dependent increases in CSF A β 42 levels were observed in cognitively normal subjects who received continuous insulin infusions compared to those who received saline infusions (Watson et al., 2003). Plasma A β 42 levels were also increased in the insulin infusion group compared to the saline infusion group, and this increase in A β 42 levels correlated with higher BMI values (Fishel et al., 2005). In another study, insulin infusion was able to induce greater percentage increases in plasma A β levels in AD patients, with no overall change in cognitively normal controls (Kulstad et al., 2006). AD patients of different ApoE genotypes may have different dose-response pattern to insulin infusion as assessed by cognitive tests as well as plasma APP levels (Craft et al., 2003). In addition to the possible mechanisms of plasma A β increases mentioned above, there may be other explanations for these observations (Kulstad et al., 2006). Insulin may act by activating insulin receptors present in the platelets and release A β via insulin signaling molecule phosphatidylinositol 3-kinase (PI3K) (Nystrom and Quon, 1999; Skovronsky et al., 2001). Insulin may also mediate plasma A β levels via LRP-1 mediated clearance of A β 40 as seen in rats (Tamaki et al., 2007), as well as by reducing the plasma level of APP in humans (Boyt et al., 2000). Finally, the observed increase in plasma A β may be secondary to enhanced efflux of A β from the brain, as can be inferred from insulin induced increased A β levels in CSF (Watson et al., 2003). Therefore, insulin infusion appears as a potential tool in modulating plasma A β levels.

Mouse

Due to the concerns about the inflammatory effects of antibody injection (Robinson et al., 2003), other compounds that have A β binding capacity without immunomodulative effects have been explored in mice. Both gelsolin (Chauhan et al., 1999) and ganglioside G_{M1} (Choo-Smith et al., 1997) bind A β with high affinity, and gelsolin also co-immunoprecipitates with A β in human plasma (Chauhan et al., 1999). Additionally, only 1% of gelsolin can cross the blood-brain barrier (Saulino and Schengrund, 1994) and G_{M1} is a large compound (86 kD) unlikely to readily enter the CNS, indicating that these compounds may be well suited for maximizing plasma levels of A β . When these agents were administered to PS/APP tg mice by intraperitoneal injection by Matsouka and colleagues, G_{M1} induced an approximate 2-fold increase of plasma A β 40 that was statistically significant. Three weeks after the initial G_{M1} administration, plasma A β 42 levels were also nearly 2-fold higher than those of vehicle treated animals. However, intraperitoneal injection of gelsolin did not alter plasma A β levels. Both compounds reduced brain A β burden, and because of their low availability to the CNS, this suggests that these compounds are acting via peripheral sink mechanisms (Matsuoka et al., 2003).

Another agent known to bind amyloid is the histological dye Congo red. While Congo red readily stains β -pleated sheet conformations of amyloid plaques, it has been reported to be a poor stain of diffuse amyloid deposits (Braak et al., 1989; Klunk et al., 1989). However, recent evidence of Congo red analogs with affinity for soluble oligomeric A β species has emerged (Maezawa et al., 2007). Intravenous administration of the Congo red derivative

Chrysamine G results in a rapid and statistically significant increase in plasma A β 40 levels, but this increase is minimal (125% of pretreatment) (Matsuoka et al., 2005). Other Congo red derivatives tested in the study did not induce an increase in plasma A β levels (Matsuoka et al., 2005).

As mentioned previously, LRP-1 is a receptor which mediates transport of A β across the BBB, as well as clearance of systemic A β by the liver (Quinn et al., 1997; Shibata et al., 2000; Deane et al., 2004;). LRP-1 binds A β with high affinity, and this binding is mediated by two domains known as cluster II and cluster IV (Deane et al., 2004). LRP-1 also has a higher affinity for A β than other LRP-1 ligands such as ApoE4 (Sagare et al., 2007), and soluble LRP is found in human plasma (Quinn et al., 1997), making it an ideal candidate for sequestration of A β in the plasma. Sagare et al. have utilized a soluble recombinant LRP fragment that encompasses cluster IV (LRP-IV) to induce peripheral sink activity in mice (Sagare et al., 2007). Intravenous administration of LRP-IV in wild-type C57BL/6 mice for 5 days resulted in a statistically significant 2-fold approximate increase in endogenous mouse A β 40, and 1.5-fold increase in endogenous mouse A β 42, as compared to vehicle injected mice. Similarly, statistically significant 2-fold increases in plasma A β 40 and A β 42 were observed in Tg2576 transgenic mice after daily i.p. injection of LRP-IV for 3 months, compared to vehicle. The plasma A β was primarily associated with LRP-IV, but LRP-IV was not found in the CSF and was not taken up by the brain (Sagare et al., 2007). This data suggests that LRP-IV may induce sequestration of plasma A β by a peripheral sink mechanism.

Lastly, the Nogo-66 receptor (NgR) limits axonal growth in the human brain and also interacts with the central domain of A β (Park et al., 2006a; Park et al., 2006b). When NgR was administered subcutaneously over a period of 3 months in the APP/PS1 mouse model of AD, there was no significant difference in the absolute A β plasma levels of NgR treated animals compared to controls. However, treatment was accompanied by reductions in brain A β levels, improvement in cognitive performance, and a significant 2-fold increase in the ratio of plasma/brain A β 42 (Park et al., 2006b). This data provides some evidence that plasma A β binding agents administered in circulation could create an efflux of A β from brain to blood.

While peripheral sequestration of A β by injection of agents with high affinity for A β appears to be a feasible approach to increase plasma A β levels, the agents tested to date have not yielded substantial increases in plasma A β as compared to vehicle. As mentioned above, considerable elevations in plasma A β may be necessary to differentiate individuals in the early stages of AD from healthy controls. Furthermore, in the studies mentioned above, the plasma A β levels after administration of the A β -binding agent have been compared either to pre-treatment plasma A β levels or to A β levels from vehicle treated transgenic animals. As demonstrated by Sagare et al., at least one of these A β binding agents, LRP-IV, is able to provoke increases in endogenous mouse A β in wild type mice, as well as increases in human A β derived from transgene expression in Tg2576 mice (Sagare et al., 2007). All humans, whether they are at risk for AD or not, produce A β . Similarly, both transgenic mice and non-transgenic mice produce some form of A β , although the levels of A β are considerably higher in transgenic mice. None of the studies above have compared the increases in plasma A β levels induced by the A β binding agent in transgenic mice versus non-transgenic mice. Although this scenario would not be an ideal representation of a diagnostic test in humans, it would be important to examine how these agents might allow differentiation of plasma samples from AD patients compared to healthy controls.

Also, a careful kinetics study to determine when the A β levels peak after administration of the A β -binding agents will be necessary since the clearance of these agents will likely vary. Lastly, as is the case with antibody-induced plasma A β levels, it is important that mice of different ages are tested with the A β -binding agents. Studies using mice with pathology ranging pre-

onset to significant amyloid plaque burden are necessary in order to determine if these agents could be useful as a preclinical diagnostic test.

Conclusion

Based on the data in humans and tg mouse models of AD, unmodified levels of plasma A β alone do not appear to be reliable as a biomarker of AD at least in cross-sectional studies, while longitudinal studies seem more promising. Many modulators of plasma A β that are under investigation in humans as well as in animal models at this time, including A β antibodies, A β binding agents and insulin. These may be important in optimizing the plasma A β levels, and may improve the diagnostic potential of plasma A β . Standardization in the processing of the plasma would be also important (Golde et al., 2000; Galasko, 2005) for the reasons discussed in this review paper. Currently there are efforts to standardize the laboratory processing of plasma biomarkers, such as in the biomarker core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) (Mueller et al., 2005). In addition, understanding of other factors such as location of A β synthesis and clearance would also play an important part in interpretation of A β as a biomarker.

Another possible approach to the utilization of A β as a biomarker of AD is the combination of this measurement with other biomarkers in the plasma, CSF, or imaging studies. A combination of multiple biomarkers would be very informative in predicting the subjects who would go on to develop AD (Ray et al., 2007). Furthermore, as many therapeutic agents that specifically target A β are under investigation at this time (Cummings et al., 2007), there is need for a biomarker that can provide information on whether these agents have affected the levels of brain A β (Galasko, 2005). The importance of plasma A β remains as a non-invasive biomarker for monitoring the efficacy of these agents.

Acknowledgements

This work was supported by the Johns Hopkins Alzheimer's Disease Research Center (National Institutes of Health Grant PO1 AG005146), John A. Hartford Foundation grant #2007-0005, Center of Excellence Renewal, at the Johns Hopkins School of Medicine, and an Anonymous Foundation. We would like to thank Dr. Abhay Moghekar and Dr. Philip Wong for their insightful comments on this manuscript.

References

- Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. *Arch Neurol* 1999;56:673–680. [PubMed: 10369305]
- Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y, Takahashi H, Fukumoto H, Horiguchi T, Suzuki N, Shoji M. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. *Neurodegener Dis* 2005a;2:36–43. [PubMed: 16909001]
- Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y, Takahashi H, Fukumoto H, Horiguchi T, Suzuki N, Shoji M. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. *Neurodegener Dis* 2005b;2:36–43. [PubMed: 16909001]
- Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. *Neurology* 2004;63:828–831. [PubMed: 15365131]
- Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. *Neurology* 2007;68:666–669. [PubMed: 17325273]
- Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. *Prog Drug Res* 2003;61:39–78. [PubMed: 14674608]

- Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. *J Biol Chem* 1996;271:32916–32922. [PubMed: 8955133]
- Boyt AA, Taddei TK, Hallmayer J, Helmerhorst E, Gandy SE, Craft S, Martins RN. The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. *Neuroscience* 2000;95:727–734. [PubMed: 10670439]
- Braak H, Braak E, Ohm T, Bohl J. Alzheimer's disease: mismatch between amyloid plaques and neuritic plaques. *Neurosci Lett* 1989;103:24–28. [PubMed: 2476692]
- Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P. The amyloid precursor protein of Alzheimer's disease is released by human platelets. *J Biol Chem* 1990;265:15977–15983. [PubMed: 2118534]
- Chauhan VP, Ray I, Chauhan A, Wisniewski HM. Binding of gelsolin, a secretory protein, to amyloid beta-protein. *Biochem Biophys Res Commun* 1999;258:241–246. [PubMed: 10329371]
- Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. *Biochem Biophys Res Commun* 1995;213:96–103. [PubMed: 7639768]
- Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of Abeta-(1–40) peptide to ganglioside-containing membrane vesicles. *J Biol Chem* 1997;272:22987–22990. [PubMed: 9287293]
- Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. *Psychoneuroendocrinology* 2003;28:809–822. [PubMed: 12812866]
- Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. *Neurology* 1988;38:1682–1687. [PubMed: 3185902]
- Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. *Neurology* 2007;69:1622–1634. [PubMed: 17938373]
- DaSilva K, Brown ME, Westaway D, McLaurin J. Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. *Neurobiol Dis* 2006;23:433–444. [PubMed: 16766202]
- de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H. MRI and CSF studies in the early diagnosis of Alzheimer's disease. *J Intern Med* 2004;256:205–223. [PubMed: 15324364]
- De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. *Neuron* 2003;38:9–12. [PubMed: 12691659]
- Deane R, Du Yan S, Subramanyam RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. *Nat Med* 2003;9:907–913. [PubMed: 12808450]
- Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. *Neuron* 2004;43:333–344. [PubMed: 15294142]
- DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* 2001;98:8850–8855. [PubMed: 11438712]
- DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. *Science* 2002a;295:2264–2267. [PubMed: 11910111]
- DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. *J Neurochem* 2002b;81:229–236. [PubMed: 12064470]

- Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. *Nat Neurosci* 2002;5:452–457. [PubMed: 11941374]
- Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B, Moller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. *Ann Neurol* 2002;52:253–256. [PubMed: 12210803]
- Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2004;75:1472–1474. [PubMed: 15377700]
- Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. *J Neurochem* 2007;103:334–345. [PubMed: 17623042]
- Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Adamson J, Schaid DJ, Blangero J, Hutton M, Younkin SG. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. *Genet Epidemiol* 2001;21:19–30. [PubMed: 11443731]
- Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR. Plasma amyloid {beta} protein is elevated in late-onset Alzheimer disease families. *Neurology* 2008;70:596–606. [PubMed: 17914065]
- Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. *J Neurosci Res* 2003;74:386–392. [PubMed: 14598315]
- Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol* 2006;59:512–519. [PubMed: 16372280]
- Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. *Arch Neurol* 2005;62:1539–1544. [PubMed: 16216936]
- Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. *J Neuropathol Exp Neurol* 2007;66:264–271. [PubMed: 17413317]
- Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. *Arch Neurol* 2003;60:958–964. [PubMed: 12873852]
- Galasko D. Biomarkers for Alzheimer's disease--clinical needs and application. *J Alzheimers Dis* 2005;8:339–346. [PubMed: 16556965]
- Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. *J Neurosci* 2001;21:2561–2570. [PubMed: 11306609]
- Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. *Neurosci Lett* 2007;427:127–131. [PubMed: 17936506]
- Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 1991;349:704–706. [PubMed: 1671712]
- Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. *Biochim Biophys Acta* 2000;1502:172–187. [PubMed: 10899442]
- Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. *Arch Neurol* 2007;64:354–362. [PubMed: 17353377]

- Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Antibody against C-terminal A β selectively elevates plasma A β . *Neuroreport* 2007;18:293–296. [PubMed: 17314674]
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002;297:353–356. [PubMed: 12130773]
- Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. *Diabetes Care* 1998;21:518–524. [PubMed: 9571335]
- Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. *J Neurosci* 2005;25:6213–6220. [PubMed: 15987951]
- Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron* 2003;38:547–554. [PubMed: 12765607]
- Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. *Ann Neurol* 2002;51:783–786. [PubMed: 12112088]
- Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K. Analysis of heterogeneous A β peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. *J Biol Chem* 1996;271:22908–22914. [PubMed: 8798471]
- Irizarry MC. Biomarkers of Alzheimer disease in plasma. *NeuroRx* 2004;1:226–234. [PubMed: 15717023]
- Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A β deposits and neuropil abnormalities, but no neuronal loss in CA1. *J Neuropathol Exp Neurol* 1997;56:965–973. [PubMed: 9291938]
- Iwatsubo T. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. *Neurobiol Aging* 1998;19:161–163. [PubMed: 9558155]
- Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature* 2000;408:979–982. [PubMed: 11140685]
- Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T. Cerebrospinal fluid A β 42 is increased early in sporadic Alzheimer's disease and declines with disease progression. *Ann Neurol* 1999;45:504–511. [PubMed: 10211475]
- Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. *Nature* 1989;341:226–230. [PubMed: 2528696]
- Kanai M, Matsubara E, Ise K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igata Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, A β 1–40, and A β 1–42(43) in Alzheimer's disease: a study in Japan. *Ann Neurol* 1998;44:17–26. [PubMed: 9667589]
- Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. *Ann Neurol* 1988;23:138–144. [PubMed: 2897823]
- Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. *J Neurosci* 2001;21:372–381. [PubMed: 11160418]
- Glunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. *J Histochem Cytochem* 1989;37:1273–1281. [PubMed: 2666510]

- Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, Asami-Odaka A, Fukushima T, Imai K, Iwatsubo T. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). *Neurology* 1997;48:741–745. [PubMed: 9065558]
- Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. *Biochem Biophys Res Commun* 1994;205:1164–1171. [PubMed: 7802646]
- Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, Craft S. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. *Neurology* 2006;66:1506–1510. [PubMed: 16717209]
- Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, Cotter RJ, Roher AE. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. *Biochem Biophys Res Commun* 1999;257:787–791. [PubMed: 10208861]
- Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. *Biochem Biophys Res Commun* 2000a;268:750–756. [PubMed: 10679277]
- Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. *Am J Pathol* 2000b;156:797–805. [PubMed: 10702395]
- Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. *J Neurosci* 2005;25:11693–11709. [PubMed: 16354928]
- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* 1998;95:6448–6453. [PubMed: 9600986]
- Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. *Neurobiol Dis* 2003;14:10–18. [PubMed: 13678662]
- Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* 2006;440:352–357. [PubMed: 16541076]
- Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. *J Clin Invest* 2006;116:193–201. [PubMed: 16341263]
- Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 1995;269:973–977. [PubMed: 7638622]
- Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am J Pathol* 1999;155:853–862. [PubMed: 10487842]
- Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, Laferla FM, Jin LW. Congo red and thioflavin-T analogs detect Abeta oligomers. *J Neurochem*. 2007
- Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. *Ann Neurol* 1999;45:537–541. [PubMed: 10211483]
- Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. *Dement Geriatr Cogn Disord* 2007;23:241–245. [PubMed: 17310121]
- Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral

- administration of agents with an affinity to beta-amyloid. *J Neurosci* 2003;23:29–33. [PubMed: 12514198]
- Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. An Abeta sequestration approach using non-antibody Abeta binding agents. *Curr Alzheimer Res* 2005;2:265–268. [PubMed: 15974928]
- Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. *Neurology* 2003;61:1185–1190. [PubMed: 14610118]
- Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD. Plasma amyloid beta-peptide 1–42 and incipient Alzheimer's disease. *Ann Neurol* 1999;46:412–416. [PubMed: 10482274]
- McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann Neurol* 1999;46:860–866. [PubMed: 10589538]
- Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. *Arch Neurol* 2000;57:100–105. [PubMed: 10634455]
- Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. *Neurosci Lett* 2001;304:102–106. [PubMed: 11335065]
- Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 2000;408:982–985. [PubMed: 11140686]
- Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. *J Mol Neurosci* 2001;17:101–118. [PubMed: 11816784]
- Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). *Alzheimers Dement* 2005;1:55–66. [PubMed: 17476317]
- Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. *Proc Natl Acad Sci U S A* 1994;91:8378–8382. [PubMed: 8078890]
- Neugroschl J, Davis KL. Biological markers in Alzheimer disease. *Am J Geriatr Psychiatry* 2002;10:660–677. [PubMed: 12427575]
- Nystrom FH, Quon MJ. Insulin Signalling: Metabolic Pathways and Mechanisms for Specificity. *Cellular Signalling* 1999;11:563–574. [PubMed: 10433517]
- Park JH, Gimbel DA, GrandPre T, Lee JK, Kim JE, Li W, Lee DH, Strittmatter SM. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. *J Neurosci* 2006a;26:1386–1395. [PubMed: 16452662]
- Park JH, Widi GA, Gimbel DA, Harel NY, Lee DH, Strittmatter SM. Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. *J Neurosci* 2006b;26:13279–13286. [PubMed: 17182778]
- Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging* 2006;27:904–905. [PubMed: 16638622]
- Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. *Annu Rev Neurosci* 1998;21:479–505. [PubMed: 9530504]
- Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann Neurol* 1999;45:358–368. [PubMed: 10072051]
- Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. *J Biol Chem* 1998;273:32730–32738. [PubMed: 9830016]

- Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. *J Biol Chem* 1997;272:23946–23951. [PubMed: 9295345]
- Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. *Nat Med* 2007;13:1359–1362. [PubMed: 17934472]
- Robinson SR, Bishop GM, Munch G. Alzheimer vaccine amyloid-beta on trial. *Bioessays* 2003;25:283–288. [PubMed: 12596233]
- Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. *Nat Med* 2007;13:1029–1031. [PubMed: 17694066]
- Saulino MF, Schengrund CL. Differential accumulation of gangliosides by the brains of MPTP-lesioned mice. *J Neurosci Res* 1994;37:384–391. [PubMed: 8176760]
- Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med* 1996;2:864–870. [PubMed: 8705854]
- Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. *Neurology* 2000;55:370–376. [PubMed: 10932270]
- Schulinkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. *Neurosci Biobehav Rev* 2000;24:855–872. [PubMed: 11118610]
- Seabrook TJ, Jiang L, Thomas K, Lemere CA. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. *J Neuroinflammation* 2006;3:14. [PubMed: 16753065]
- Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. *J Clin Invest* 2002;110:1375–1381. [PubMed: 12438432]
- Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. *Science* 1997;275:630–631. [PubMed: 9019820]
- Selkoe DJ. Clearing the Brain's Amyloid Cobwebs. *Neuron* 2001;32:177–180. [PubMed: 11683988]
- Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 1995;375:754–760. [PubMed: 7596406]
- Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J Clin Invest* 2000;106:1489–1499. [PubMed: 11120756]
- Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of gamma-Secretase. *Clin Neuropharmacol* 2007;30:317–325. [PubMed: 18090456]
- Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. *Neurology* 2006;66:602–604. [PubMed: 16505324]
- Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. *Lancet Neurol* 2003;2:506–511. [PubMed: 12878439]
- Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaa SM, Wang S, Walker D, Zhao J, McConlogue L, John V.

- Purification and cloning of amyloid precursor protein beta-secretase from human brain. *Nature* 1999;402:537–540. [PubMed: 10591214]
- Skovronsky DM, Lee VM, Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. *J Biol Chem* 2001;276:17036–17043. [PubMed: 11278299]
- Slemmon JR, Painter CL, Nadanaciva S, Catana F, Cook A, Motter R, Seubert P. Distribution of Abeta peptide in whole blood. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007;846:24–31.
- Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. *Neuron* 2006;52:15–31. [PubMed: 17015224]
- Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. *Ann Neurol* 2005;58:147–150. [PubMed: 15984012]
- Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnema E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L. Plasma {beta} Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study. *Arch Neurol* 2008;65:256–263. [PubMed: 18268197]
- Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM. Decreased beta-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. *JAMA* 2003;289:2094–2103. [PubMed: 12709467]
- Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. *Eur J Neurosci*. 2007
- Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, Terasaki T. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. *Pharm Res* 2006;23:1407–1416. [PubMed: 16779710]
- Tamaki C, Ohtsuki S, Terasaki T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1–40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. *Mol Pharmacol* 2007;72:850–855. [PubMed: 17609417]
- Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, Shoji S. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. *J Neurol Sci* 1996;141:65–68. [PubMed: 8880695]
- Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. *Neuron* 2004;43:605–608. [PubMed: 15339642]
- Tokuda T, Fukushima T, Ikeda S, Sekijima Y, Shoji S, Yanagisawa N, Tamaoka A. Plasma levels of amyloid beta proteins Abeta1–40 and Abeta1–42(43) are elevated in Down's syndrome. *Ann Neurol* 1997;41:271–273. [PubMed: 9029078]
- Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. *Neurobiol Aging* 1996;17:365–371. [PubMed: 8725897]
- van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1–40) and Abeta(1–42) and the risk of dementia: a prospective case-cohort study. *Lancet Neurol* 2006;5:655–660. [PubMed: 16857570]
- Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E. Standardization of measurement of beta-amyloid(1–42) in cerebrospinal fluid and plasma. *Amyloid* 2000;7:245–258. [PubMed: 11132093]
- Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science* 1999;286:735–741. [PubMed: 10531052]

- Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 2002;416:535–539. [PubMed: 11932745]
- Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S. Insulin increases CSF Abeta42 levels in normal older adults. *Neurology* 2003;60:1899–1903. [PubMed: 12821730]
- Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. *Nat Med* 2003;9:3–4. [PubMed: 12514700]
- Zamora E, Handisurya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC, Kimbaurer R. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. *J Immunol* 2006;177:2662–2670. [PubMed: 16888028]

Figure 1.

Amyloid-beta (Aβ) 1–40 and 1–42 are synthesized in the brain (Laird et al., 2005), (1), as well as in the periphery (Irizarry et al., 1997; Joachim et al., 1989; Vassar et al., 1999) (2). Circulating Aβ peptides enter the blood stream (3) and are partly cleared by the LRP-1 receptors in the liver (Tamaki et al., 2006) (4). Soluble extracellular brain Aβ (5) may accumulate in the brain parenchyma as amyloid plaques. Receptor mediated movement of the soluble Aβ through the blood brain barrier (BBB) (6) is mediated by transporters such as low-density lipoprotein receptor-related protein-1 (LRP-1) (Deane et al., 2004; Shibata et al., 2000) for efflux, and receptor for advanced glycation end products (RAGE) (Deane et al., 2003) for influx. Once in the blood, Aβ peptides are bound by numerous binding proteins such as ApoE (Tanzi et al., 2004), albumin (Biere et al., 1996), and others (7). Aβ specific IgG is also able to bind Aβ peptide in the blood, and may induce efflux of Aβ from the brain to the blood via the “peripheral sink” mechanism (DeMattos et al., 2001).

Table 1

Plasma A β 40, 42 and 42/40 ratios in sporadic AD (sAD) versus controls. Studies that investigated subjects with mild cognitive impairment (MCI) and cognitively normal subjects who were followed longitudinally were also included. Some studies show changes in plasma A β levels with disease progression (Mayeux et al., 2003) while others did not (Pesaresi et al., 2006). Plasma A β did not vary with cognitive scores (Fukumoto et al., 2003; Mehta et al., 2000; Mehta et al., 2001; Pesaresi et al., 2006), APO E status (Fukumoto et al., 2003; Mayeux et al., 1999; Mayeux et al., 2003; Pesaresi et al., 2006; Vanderstichele et al., 2000), or education (Mayeux et al., 1999). Some studies have reported an effect of APOE on plasma A β (Graff-Radford et al., 2007; Mehta et al., 2000).

	Studies	Able to Detect Differences in sAD vs. Controls or Predict Future sAD		
		A β 40	A β 42	A β 42/40 ratio
Cross-sectional	Scheuner, D. et.al, 1996 (Scheuner et al., 1996)	No	No	
	Tamaoka, D. et.al, 1996 (Tamaoka et al., 1996)	No	No	
	Kosaka, T. et.al, 1997 (Kosaka et al., 1997)	No	No	
	Iwatsubo, T. et.al, 1998 (Iwatsubo, 1998)	No	No	
	Matsubara, E. et.al, 1999* (Matsubara et al., 1999)	Yes	Yes	
	Metha, P.D. et.al, 2000 [†] (Mehta et al., 2000)	No	No	
	Vanderstichele, H. et.al, 2000 (Vanderstichele et al., 2000)	No	No	
	Metha, P.D. et.al, 2001 (Mehta et al., 2001)	No	No	
	Fukumoto, H. et.al, 2003 (Fukumoto et al., 2003)	No	No	
	Assini, A. et.al 2004 [‡] (Assini et al., 2004)	No	Yes	
	van Oijen, M. et.al 2006 ^{**} (van Oijen et al., 2006)	Yes	No	Yes
	Pesaresi, M. et.al 2006 [‡] (Pesaresi et al., 2006)		Yes	
	Giedraitis, V. et.al, 2007 (Giedraitis et al., 2007)	No	No	
Longitudinal	Mayeux, R. et.al, 1999 [∞] (Mayeux et al., 1999)	No	Yes	Yes
	Mayeux, R. et.al, 2003 (Mayeux et al., 2003)	No	Yes	
	Graff-Radford, N.R. et.al 2007 [§] (Graff-Radford et al., 2007)	No	No	Yes
	Sundelof, J. et.al 2008 [¥] (Sundelof et al., 2008)	Yes	No	

* This study quantified A β 40, 42 species in the native and lipoprotein-depleted (LPDP) plasma. The results shown are the LPDP samples.

[†] The levels of plasma A β 40 were significantly higher in the AD group than the controls ($p = 0.005$), however these measurements were stated to be not useful as a diagnostic tool due to a considerable overlap between the two groups.

[‡] Overall comparison of the plasma A β 42 levels between the MCI group and age matched controls did not show a significant difference. Sub-group analysis based on gender showed significantly higher A β 42 levels in female MCI subjects as compared to female controls ($p < 0.05$).

** This study reported similar association between plasma A β levels and dementia and between plasma A β levels and its subtype Alzheimer's disease. Lower A β 42/40 ratio associated with increased risk for dementia.

[‡] There was no plasma A β 40 levels reported in this study. A subset of patients were followed for 18 months.

[∞] This study reported a higher A β 42, 40 and 42/40 at baseline in subjects who subsequently developed AD compared to controls; however, baseline A β 42 and higher A β 42/A β 40 ratio levels were associated with increased risk of AD. Higher A β 42/40 ratio associated with increased risk for AD.

[§] This study reported a lower A β 42/40 at baseline in subjects who subsequently developed AD compared to controls. Lower A β 42/40 ratio associated with increased risk for MCI/AD

[¥] This effect was shown in elderly men (≥ 77 years old at baseline), but not in youngermen (70 years old at baseline).

Table 2**Mouse plasma A β levels after A β antibody administration**

Author	Antibody administered	Mouse model	A β species	Fold A β increase [†]
DeMattos (2001) (DeMattos et al., 2001)	500 μ g m266 600 μ g m266	PDAPP	A β _{total} A β _{total}	1000 [‡] ~600
Dodart (2002) (Dodart et al., 2002)	360 μ g m266	PDAPP	A β ₄₀ A β ₄₂	150 70
Lemere (2003) (Lemere et al., 2003)	Active vaccination	PS-APP	A β _{total}	28
Hartman (2005) (Hartman et al., 2005)	500 μ g 10D5	PDAPP	A β ₄₀ A β ₄₂	~2.5 ~25
Asami-Odaka (2005) (Asami-Odaka et al., 2005b)	BC05 [#]	Tg2576	A β ₄₀ A β ₄₂	-0.3 [§] 22
DaSilva (2006) (DaSilva et al., 2006)	Active vaccination	TgCRND8	A β ₄₀ A β ₄₂	2 2
Seabrook (2006) (Seabrook et al., 2006)	Active vaccination	J20 APP	A β _{total}	N.S.
Zamora (2006) (Zamora et al., 2006)	Active vaccination	APP/PS1 (Line 85)	A β ₄₀ A β ₄₂	N.S. N.S.
Levites (2006) (Levites et al., 2006)	500 μ g Ab9	Tg2576	A β ₄₀ A β ₄₂	15 25
Gray (2007) (Gray et al., 2007)	50 μ g 6E10 50 μ g 1A10 [#]	Tg2576	A β ₄₀ A β ₄₂ A β ₄₀ A β ₄₂	~10 ~2 ~5 N.S.
Takata (2007) (Takata et al., 2007)	50 μ g 6E10 50 μ g 82E1 [¥] 250 μ g 82E1 [¥]	3xTg-AD	A β _{total}	2 5 2.5

[†]In some cases, the fold increase of A β over baseline was estimated (~) based on reported data. N.S. = non-significant difference

[‡]This increase in A β was measured by Western blot

[#]These are antibodies raised against the C-terminus of A β

[§]This study reported a 30% reduction in A β ₄₀ levels after antibody administration

[¥]This is a deglycosylated antibody